[go: up one dir, main page]

AR011077A1 - Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion - Google Patents

Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion

Info

Publication number
AR011077A1
AR011077A1 ARP980100207A ARP980100207A AR011077A1 AR 011077 A1 AR011077 A1 AR 011077A1 AR P980100207 A ARP980100207 A AR P980100207A AR P980100207 A ARP980100207 A AR P980100207A AR 011077 A1 AR011077 A1 AR 011077A1
Authority
AR
Argentina
Prior art keywords
methylerythromycin
solvate
mammal
suspension
bacterial infections
Prior art date
Application number
ARP980100207A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR011077A1 publication Critical patent/AR011077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un antibiotico cristalino designado forma 0 de solvato de 6-O- metileritromicina A, que tiene la estructura (S), donde S es una moléculasolvatante seleccionada del grupo que consiste en etanol, acetato de ispropilo, isopropanol y tetrahidrofurano; una composicion que lo comprende, unmétodo para tratar infecciones bacterianas en un mamífero, un procedimiento para su preparacion y una suspension para administracion oral.
ARP980100207A 1997-01-17 1998-01-16 Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion AR011077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin

Publications (1)

Publication Number Publication Date
AR011077A1 true AR011077A1 (es) 2000-08-02

Family

ID=25136084

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980100207A AR011077A1 (es) 1997-01-17 1998-01-16 Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion
ARP030101427A AR039666A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma i de 6-o-metileritromicina a al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para prepararla forma i de 6-o-metileritromicina a y otros derivados
ARP030101428A AR039667A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma ii de 6-o-metileritromicina al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para preparar la forma ii de 6-o-metileritromicina a y otros derivados

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP030101427A AR039666A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma i de 6-o-metileritromicina a al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para prepararla forma i de 6-o-metileritromicina a y otros derivados
ARP030101428A AR039667A2 (es) 1997-01-17 2003-04-24 Procedimiento para la preparacion de la forma ii de 6-o-metileritromicina al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para preparar la forma ii de 6-o-metileritromicina a y otros derivados

Country Status (18)

Country Link
US (1) US5945405A (es)
EP (1) EP1077988A1 (es)
JP (3) JP4058114B2 (es)
KR (1) KR100567149B1 (es)
CN (1) CN1174991C (es)
AR (3) AR011077A1 (es)
AU (1) AU735598B2 (es)
BR (1) BR9714287A (es)
CA (4) CA2387356C (es)
CZ (1) CZ297433B6 (es)
DE (1) DE97951771T1 (es)
ES (1) ES2173058T1 (es)
IL (1) IL130255A0 (es)
NZ (1) NZ336073A (es)
TR (1) TR199901578T2 (es)
TW (1) TW574224B (es)
WO (1) WO1998031699A1 (es)
ZA (1) ZA98116B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
YU45602A (sh) * 1999-12-16 2005-06-10 Teva Pharmaceutical Industries Ltd. Postupci za dobijanje polimorfa klaritromicina i novi polimorf iv
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
DE60018119T2 (de) * 2000-01-11 2006-05-04 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von polymorphen des clarithromycins
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CA2401571A1 (en) * 2000-02-29 2001-09-07 Ilya Avrutov Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
ES2242668T3 (es) * 2000-03-15 2005-11-16 Hanmi Pharm. Co., Ltd. Metodo para obtener claritromicina en cristales de forma ii.
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
MXPA02009587A (es) * 2000-03-28 2003-05-14 Biochemie Gmbh Particulas granuladas con sabor enmascarado.
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
DE60143360D1 (de) * 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
PT1411899E (pt) * 2001-08-01 2009-04-24 Novartis Ag Composição de mascaramento de sabor
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
DK0915899T3 (da) * 1996-07-29 2004-11-29 Abbott Lab Fremstilling af krystallinsk form II af clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Also Published As

Publication number Publication date
CA2387356C (en) 2003-05-27
CN1244869A (zh) 2000-02-16
CA2387361C (en) 2003-05-27
JP2004075689A (ja) 2004-03-11
KR20000070220A (ko) 2000-11-25
CA2419499A1 (en) 1998-07-23
KR100567149B1 (ko) 2006-04-04
CA2387356A1 (en) 1998-07-23
BR9714287A (pt) 2000-04-18
JP2009137975A (ja) 2009-06-25
CZ297433B6 (cs) 2006-12-13
CA2277274C (en) 2003-05-27
TR199901578T2 (xx) 1999-09-21
AU735598B2 (en) 2001-07-12
JP5190350B2 (ja) 2013-04-24
DE97951771T1 (de) 2004-07-08
IL130255A0 (en) 2000-06-01
TW574224B (en) 2004-02-01
WO1998031699A1 (en) 1998-07-23
AR039666A2 (es) 2005-03-02
CA2277274A1 (en) 1998-07-23
ZA98116B (en) 1998-07-08
EP1077988A1 (en) 2001-02-28
AR039667A2 (es) 2005-03-02
NZ336073A (en) 2001-01-26
US5945405A (en) 1999-08-31
CA2387361A1 (en) 1998-07-23
CZ242699A3 (cs) 1999-11-17
ES2173058T1 (es) 2002-10-16
CN1174991C (zh) 2004-11-10
JP2000509725A (ja) 2000-08-02
AU5532698A (en) 1998-08-07
JP4058114B2 (ja) 2008-03-05

Similar Documents

Publication Publication Date Title
AR011077A1 (es) Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion
RU95106362A (ru) Производные липопептида, способ их получения, содержащая их фармацевтическая композиция и способ ее получения
NO2005020I2 (no) Caspofungin, eventuelt i form av et farmasoeytisk akseptabelt salt saerlig caspofungiacetat
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
ES2196331T3 (es) Derivados macrociclicos de cadena de 13 elementos de las eritromicinas a y b.
SE7613959L (sv) Antibiotisk komposition och forfarande for framstellning derav
MA26458A1 (fr) Nouveaux derives cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE69728420D1 (de) Methoden zur behandlung von durch chlamydia pneumoniae verursachten herzkrankheiten
PT1042340E (pt) Oxima de 6-o-alquil-eritromicina b
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
DE58908740D1 (de) Pilzart Tolypocladium varium und Verfahren zur Herstellung des Antibioticumkomplexes Cyclosporin und/oder seiner Bestandteile.
EP0992509A3 (en) Novel macrolide derivatives
EP0137440A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
DE2967701D1 (de) A-21978 genannte antibiotische mischung, verfahren zu ihrer herstellung, ihre pharmazeutischen zusammensetzungen und produzierender mikroorganismus.
MD1788F2 (en) Erythromycin A 9-O-oximes derivatives, pharmaceutical composition on base thereof and method of treatment of infectious diseases
DE69012650D1 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
DK1007530T3 (da) 6-O-substituerede erythromycinforbindelser samt fremgangsmåde til fremstilling heraf
ATE66610T1 (de) Primycin enthaltendes kolloidales grundgel, verfahren zu dessen herstellung, dieses grundgel enthaltende pharmazeutische und pharmako- kosmetische kompositionen.
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
RU94007342A (ru) Новые производные эритромицина, метод их получения и фармацевтическая композиция на их основе
HUT57774A (en) Process for producing triacetate derivative of antibiotic bu-3420t, as well as pharmaceutical compositions comprising bu-3420t triacetate
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
DK1181300T3 (da) 6-O-carbamatketolidderivater

Legal Events

Date Code Title Description
FC Refusal